

**ROCTAVIAN**<sup>®</sup> ▼  
(valoctocogene roxaparvovec)

Wednesday 5<sup>th</sup> February 2025

15:30–16:45 CET

# The Patient Journey

Professor Cedric Hermans  
Professor Dario Di Minno  
Dr Amit Soni

“I no longer feel  
there’s a limit,  
that’s the past”

Steven, South Africa

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. ROCTAVIAN<sup>®</sup> is indicated for the treatment of severe haemophilia A (congenital factor VIII deficiency) in adult patients without a history of factor VIII inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (AAV5). Prescribing information can be found [here](#).

**BioMARIIN**

This symposium has been initiated and sponsored by BioMarin. © 2024 BioMarin International Ltd. All Rights Reserved. For Healthcare Professionals Only. EUCAN-ROC-00369 12/24

 **ROCTAVIAN**<sup>®</sup>  
(valoctocogene roxaparvovec)  
Solution for intravenous infusion